JP2021534115A5 - - Google Patents
Info
- Publication number
- JP2021534115A5 JP2021534115A5 JP2021506716A JP2021506716A JP2021534115A5 JP 2021534115 A5 JP2021534115 A5 JP 2021534115A5 JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021534115 A5 JP2021534115 A5 JP 2021534115A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- heterocyclyl
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718929P | 2018-08-14 | 2018-08-14 | |
| US62/718,929 | 2018-08-14 | ||
| US201862775797P | 2018-12-05 | 2018-12-05 | |
| US62/775,797 | 2018-12-05 | ||
| US201962836511P | 2019-04-19 | 2019-04-19 | |
| US62/836,511 | 2019-04-19 | ||
| PCT/US2019/046411 WO2020036999A1 (en) | 2018-08-14 | 2019-08-13 | Treatment of b cell malignancies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534115A JP2021534115A (ja) | 2021-12-09 |
| JP2021534115A5 true JP2021534115A5 (https=) | 2022-08-19 |
Family
ID=69525845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506716A Pending JP2021534115A (ja) | 2018-08-14 | 2019-08-13 | Ｂ細胞悪性腫瘍の処置 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210299134A1 (https=) |
| EP (1) | EP3836935A4 (https=) |
| JP (1) | JP2021534115A (https=) |
| KR (1) | KR20210043635A (https=) |
| CN (1) | CN112888441A (https=) |
| AU (1) | AU2019321432A1 (https=) |
| BR (1) | BR112021002760A2 (https=) |
| CA (1) | CA3109184A1 (https=) |
| IL (1) | IL280726A (https=) |
| MA (1) | MA53236A (https=) |
| MX (1) | MX2021001606A (https=) |
| SG (1) | SG11202101450VA (https=) |
| TW (1) | TW202021591A (https=) |
| WO (1) | WO2020036999A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011338530B2 (en) * | 2010-12-06 | 2017-06-15 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
| TWI572599B (zh) * | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| HUE049175T2 (hu) * | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| WO2017007658A1 (en) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| KR20180042356A (ko) * | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| EP3487878A4 (en) * | 2016-07-20 | 2020-03-25 | University of Utah Research Foundation | CD229-CAR-T CELLS AND METHOD FOR USE THEREOF |
| IL292938A (en) * | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combined treatment |
| WO2018060833A1 (en) * | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| WO2018082444A1 (zh) * | 2016-11-02 | 2018-05-11 | 叶宝欢 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| KR20200041358A (ko) * | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
-
2019
- 2019-08-13 SG SG11202101450VA patent/SG11202101450VA/en unknown
- 2019-08-13 EP EP19849451.0A patent/EP3836935A4/en not_active Withdrawn
- 2019-08-13 AU AU2019321432A patent/AU2019321432A1/en not_active Abandoned
- 2019-08-13 MA MA053236A patent/MA53236A/fr unknown
- 2019-08-13 MX MX2021001606A patent/MX2021001606A/es unknown
- 2019-08-13 CA CA3109184A patent/CA3109184A1/en active Pending
- 2019-08-13 WO PCT/US2019/046411 patent/WO2020036999A1/en not_active Ceased
- 2019-08-13 CN CN201980067607.2A patent/CN112888441A/zh active Pending
- 2019-08-13 KR KR1020217007417A patent/KR20210043635A/ko not_active Ceased
- 2019-08-13 BR BR112021002760-2A patent/BR112021002760A2/pt not_active IP Right Cessation
- 2019-08-13 US US17/268,052 patent/US20210299134A1/en not_active Abandoned
- 2019-08-13 JP JP2021506716A patent/JP2021534115A/ja active Pending
- 2019-08-14 TW TW108128967A patent/TW202021591A/zh unknown
-
2021
- 2021-02-08 IL IL280726A patent/IL280726A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517116A5 (https=) | ||
| JP2024507938A5 (https=) | ||
| JP2021534115A5 (https=) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| RU2018137687A (ru) | Фармацевтические комбинации для лечения злокачественной опухоли | |
| JP2020531414A5 (https=) | ||
| JP2015536986A5 (https=) | ||
| BRPI0916694B1 (pt) | uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos | |
| RU2020109775A (ru) | Комплексная терапия | |
| JP2014524469A5 (https=) | ||
| JP2022540421A5 (https=) | ||
| KR20160128456A (ko) | 이미다조옥사진 화합물에 의한 항종양 효과 증강제 | |
| JP2012528099A (ja) | Ｐｌｋ１阻害剤および抗腫瘍剤を含む治療組合せ | |
| JP2018503610A5 (https=) | ||
| CN101484443B (zh) | 放射线治疗增强剂 | |
| JP2021534116A5 (https=) | ||
| US20130101680A1 (en) | Radiotherapy enhancer | |
| JP2016502540A5 (https=) | ||
| JP2021534114A5 (https=) | ||
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| JP5976923B2 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2023514426A5 (https=) | ||
| JPH0120128B2 (https=) | ||
| JPS6337767B2 (https=) | ||
| EA047153B1 (ru) | Способы лечения гематологических злокачественных новообразований с применением 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона |